BioAgilytix Closes Acquisition of Australia-based 360biolabs (R)

BioAgilytix

2021/10/14 20:05

PR92315

 

DURHAM, N.C., Oct. 14, 2021 /PRNewswire=KYODO JBN/ --

 

-- Following final government approval, 360biolabs, a BioAgilytix company, adds

world-class virology & immunology expertise and LC/MS/MS small molecule

capabilities to the company, enabling support of bioanalytical services across

all geographies and development stages

 

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research

organization focused on supporting pharmaceutical and biotech partners in all

phases of drug development, announced today that, following Australian Foreign

Investment Review Board ("FIRB") approval, it officially closed the purchase of

360biolabs(R). The acquisition of the company, now known as 360biolabs, a

BioAgilytix company, expands BioAgilytix's capabilities into first-in-human

trials (FIH), early-phase clinical trials and adds additional capacity by

joining 360biolabs' internationally recognized quality systems in Melbourne and

Brisbane with its existing laboratories in Durham, North Carolina; Boston,

Massachusetts; San Diego, California and Hamburg, Germany.

 

Logo -

https://mma.prnewswire.com/media/1659727/360biolabs_logo_RGB_tagline_Logo.jpg

 

Located in Australia's biomedical and clinical research hubs, Victoria and

Queensland, 360biolabs offers world-class virology and immunology expertise,

with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities

with a state-of-the-art flow cytometry suite, molecular biology PCR suite and

expansive bioanalytical LC/MS/MS small molecule capabilities.

 

"We are delighted to announce the final close of the 360biolabs acquisition, as

it's such positive and exciting news for our global team and customers. Our

expanded capacity, expertise and agility to now serve clients across all

geographies is unprecedented," said Jim Datin, President and CEO of

BioAgilytix. "360biolabs' leadership position in virology and immunology, plus

their small molecule capabilities and locations in Melbourne and Brisbane, help

make BioAgilytix an end-to-end bioanalytical force dedicated to helping

generate new innovations and life-changing therapeutics for patients around the

world."  

 

"Our team is thrilled to formally join forces with BioAgilytix, as we already

share so much culturally, from our mutual strong scientific track record to our

commitment to quality science enabling innovative medicines to be developed for

patients. Together we will provide an exceptional range of specialized assays

and services to fulfill our clients' high expectations on a global scale," said

Alistair Draffan, CEO of 360biolabs. "We have no doubt that the combined group

is more than up to the task of tackling the world's many health challenges,

whether the pandemic or treatments for unmet clinical needs."

 

BioAgilytix selected White & Case as legal counsel to oversee the closing of

the acquisition, with Lazards Australia and Allens representing 360biolabs.

 

About BioAgilytix

BioAgilytix is a leading global contract research organization focused on

supporting pharmaceutical and biotech partners in all phases of drug

development. With laboratory locations in North Carolina's Research Triangle

Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane,

Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity,

biomarkers, and cell-based assay services supporting the development and

release testing of therapeutics across a number of industries and disease

states.

 

BioAgilytix offers assay development, validation, and sample analysis under

non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product

release testing, stability testing, etc.) BioAgilytix also offers diagnostic

testing services at its CLIA-certified, CAP-accredited Boston laboratory.

 

BioAgilytix's team of highly experienced scientific and QA professionals

ensures high-quality science, data integrity and regulatory compliance through

all phases of clinical development. BioAgilytix is a trusted partner to many

top global pharmaceutical and biotech companies. For more information, visit

www.bioagilytix.com.

 

About 360biolabs(R), a BioAgilytix company 360biolabs(R), a BioAgilytix

company, is the leading and most comprehensive specialty laboratory in the

Australia and New Zealand region. Our expert pharmacokinetic (PK) and

pharmacodynamic (PD) assay services support small molecule, biologic, vaccine

and other innovative therapeutic solutions to human health. A world class and

industry experienced technical team, known for their ability to successfully

deliver technically challenging assays, 360biolabs® supports global

pharmaceutical and biotech companies in a diverse and growing range of

therapeutics areas.

 

360biolabs(R) delivers global regulatory compliant assays and reports following

ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality.

For more information, visit www.360biolabs.com.

 

Media Contact:

Pam O'Connor

BioAgilytix

+1 919-621-1230

pam.oconnor@bioagilytix.com

 

 

 

SOURCE: BioAgilytix  

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中